The Broad Institute of MIT and Harvard is seeking an outstanding Postdoctoral Associate candidate to join the Priming Agent Teaman exciting multidisciplinary and multi-lab collaboration led by Viktor Adalsteinsson (Gerstner Center for Cancer Diagnostics at Broad) Sangeeta Bhatia (MIT) and J. Christopher Love (MIT)that seeks to unlock the power of liquid biopsies for cancer diagnostics by addressing critical biological bottlenecks.
The goal of the Priming Agent Team is to develop the first diagnostic drugs for liquid biopsies that improve the recovery of circulating tumor DNA (ctDNA) to enable early cancer detection monitoring for minimal residual disease and minimally-invasive tumor genotyping from blood samples (see Martin-Alonso et al Science 2024).
We are seeking an exceptionally motivated individual to pursue next generation strategies involving protein engineering nanoparticle engineering drug delivery and/or synthetic biology approaches to elucidate mechanisms of ctDNA shedding and develop pharmacologically-driven approaches to enable liquid biopsy cancer detection of otherwise low ctDNA-shedding tumors.
Our team includes scientists engineers medical oncologists and computational biologists spanning the Broad Institute MIT Harvard and Harvard-affiliated hospitals and the successful candidate will gain exposure to cutting-edge science through meetings symposia and interactions with colleagues and collaborators.
QUALIFICATIONS
Ph.D. in Bioengineering or related field and/or M.D. required
Deep biological understanding and technical skills
Exceptionally innovative and rigorous in problem-solving
Proven track record in scientific research and publications
Thrives in a fast-paced environment and enjoys collaborating with others
Strong interpersonal organizational communication and leadership skills
Experience with mouse models is preferred
Required Experience:
IC
Broad Institute is a multidisciplinary community of researchers on a mission to improve human health.